Oral Estradiol Cost in Delaware 2026

What Does Oral Estradiol Actually Cost in Delaware Right Now?

The average cash-pay price for oral estradiol at Delaware retail pharmacies sits at approximately $15 per month in 2026. That number covers standard generic tablets (0.5 mg, 1 mg, or 2 mg) dispensed at a 30-day supply. The manufacturer list price for the same generics is posted at around $40 per month, but almost no patient pays that figure at the counter.

The gap between list price and actual retail price exists because pharmacy benefit managers negotiate downward, and because multiple generic manufacturers compete in this market. Pfizer, Amneal, and Teva each produce FDA-approved oral estradiol tablets, and that competition keeps shelf prices low. Delaware has 47 retail pharmacies within New Castle County alone, so comparison shopping between chains can shave another few dollars off a monthly fill.

Prices do vary by pharmacy. A 30-day supply of estradiol 1 mg tablets might run $9 at a Costco or Sam's Club pharmacy versus $22 at a regional independent pharmacy. Using a free discount card (see GoodRx, NeedyMeds, or the pharmacy's own savings program) at the time of checkout generally brings the price into the $8 to $18 range at most Delaware locations. The FDA-approved prescribing information for oral estradiol tablets confirms the approved indications and standard dosing intervals.

Price transparency tools such as GoodRx show real-time Delaware-specific prices by ZIP code. Wilmington, Dover, and Newark ZIP codes each return slightly different results based on local pharmacy competition.

Delaware Medicaid Coverage for Oral Estradiol

Delaware Medicaid (administered through the Delaware Medical Assistance Program, or DMAP) covers oral estradiol for moderate-to-severe vasomotor symptoms of menopause, but it requires a prior authorization (PA) before the claim will process. Without an approved PA, the pharmacy claim will reject at the point of sale.

The PA process through DMAP typically asks the prescriber to document that the patient has a confirmed menopausal or perimenopausal diagnosis, that symptoms are moderate to severe, and that no contraindication to estrogen therapy is present. Prescribers familiar with this workflow say most straightforward cases are approved within two to five business days. The Delaware Division of Medicaid and Medical Assistance publishes its preferred drug list (PDL) on the DMAP website, and oral estradiol appears there as a covered product subject to PA.

Once the PA is approved, the Medicaid-enrolled patient's copay for a Tier 1 generic is generally $0 to $3 per fill under Delaware's standard Medicaid drug benefit structure. That makes Medicaid by far the lowest-cost pathway for eligible patients.

Patients enrolled in a Delaware Medicaid managed care organization (MCO), such as AmeriHealth Caritas Delaware or Highmark Health Options Delaware, should confirm PA criteria with their specific plan, as MCOs may apply slightly different step-therapy requirements. The underlying state Medicaid statute follows federal Medicaid drug coverage rules under 42 CFR 447.512.

How Does Compounded Oral Estradiol Work in Delaware?

Compounded estradiol from a licensed 503A pharmacy is legal in Delaware and may be obtained at zero or very low out-of-pocket cost for some patients. 503A refers to the section of the federal Food, Drug, and Cosmetic Act that governs patient-specific compounding by state-licensed pharmacies. In Delaware, the Board of Pharmacy licenses and inspects 503A compounding facilities under Title 24, Chapter 25 of the Delaware Code.

A prescriber must write a patient-specific prescription (not a standing order for office stock) for a 503A-compounded estradiol preparation. The pharmacy then compounds it for that individual patient. Common reasons a clinician might prescribe compounded rather than commercially manufactured oral estradiol include:

• A patient needing a dose not available commercially (for example, 0.25 mg)
• A patient with a documented allergy to an excipient in every commercially available tablet
• A situation where the commercial product is on backorder

The cost of compounded estradiol from a Delaware 503A pharmacy varies by formulation, but some practices that dispense through concierge or cash-pay membership models report $0 copay for patients enrolled in their programs. Outside those programs, compounded oral estradiol capsules typically run $20 to $45 per month at Delaware compounding pharmacies, depending on dose and capsule count.

The FDA does not approve compounded preparations, which means no efficacy or safety data specific to a given compounded product has been reviewed by the agency. The FDA's guidance on compounded drug products under sections 503A and 503B of the FD&C Act explains this regulatory distinction in detail.

Patients considering compounded estradiol should discuss the regulatory context with their prescriber. The clinical data underlying hormone therapy efficacy comes from trials using FDA-approved formulations.

Clinical Evidence Supporting Oral Estradiol Use

Oral estradiol is one of the most studied medications in women's health. The Women's Health Initiative (WHI), published in JAMA in 2002 (N=16,608 for the combined estrogen-plus-progestin arm), remains the most widely cited large-scale randomized controlled trial of menopausal hormone therapy. The WHI estrogen-plus-progestin trial reported a hazard ratio of 1.26 for invasive breast cancer, which led to substantial re-evaluation of long-term hormone therapy use. Importantly, the WHI used conjugated equine estrogen (0.625 mg) plus medroxyprogesterone acetate, not 17-beta estradiol, a distinction that matters when applying those findings to modern estradiol prescribing.

Subsequent analyses have helped clarify risk stratification. The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement states: "For women who are younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms." That guideline is among the most frequently cited in clinical practice for estradiol prescribing decisions.

A 2017 Cochrane review of short-term oral estradiol for vasomotor symptoms (17 trials, N=3,505) found that estradiol significantly reduced hot flash frequency compared with placebo, with a standardized mean difference of -0.80 (95% CI -0.99 to -0.62, P<0.001). That effect size is clinically meaningful: it corresponds roughly to a 75% reduction in hot flash frequency for many patients.

The standard starting dose for moderate-to-severe vasomotor symptoms is estradiol 1 mg orally once daily, titrated after 8 to 12 weeks based on symptom response and tolerability. The FDA-approved dose range for oral tablets spans 0.5 mg to 2 mg daily.

Insurance Coverage Beyond Medicaid

Commercial insurance plans sold in Delaware through the ACA marketplace, employer-sponsored plans, and Medicare Part D each handle oral estradiol differently. Here is a practical breakdown:

ACA marketplace plans. Under the Affordable Care Act, non-grandfathered plans must cover FDA-approved prescription drugs on formulary. Most Delaware marketplace plans (Highmark BCBS Delaware, Aetna CVS Health) list generic oral estradiol on Tier 1 or Tier 2. A Tier 1 generic copay typically runs $0 to $10 per fill; a Tier 2 generic runs $15 to $45, depending on plan design.

Employer-sponsored plans. Coverage varies widely. Most large-employer plans in Delaware with a standard pharmacy benefit include generic estradiol at the generic copay tier, usually $5 to $20 per fill. Patients should check their Summary of Benefits and Coverage (SBC) document or call member services to confirm tier placement and any quantity or age limits.

Medicare Part D. Oral estradiol appears on most Part D formularies, typically at Tier 1 or Tier 2. In 2026, the Medicare Part D redesign (Inflation Reduction Act) caps out-of-pocket drug costs at $2,000 per year for all Part D enrollees, which effectively eliminates catastrophic cost exposure for patients on estradiol alone. The standard Part D deductible in 2026 is $590.

TRICARE. Delaware has a notable military population near Dover Air Force Base. TRICARE covers oral estradiol for active-duty family members and retirees; generic copays through retail TRICARE pharmacies are $11 for a 30-day supply or $0 through the TRICARE mail-order pharmacy for a 90-day supply.

Getting Oral Estradiol via Telehealth in Delaware

Telehealth prescribing of oral estradiol is permitted in Delaware. The Delaware Telehealth Access Act (codified at 16 Del. C. Ch. 1, Section 122(3)(aa)) requires that telehealth providers meet the same standard of care as in-person providers, but does not prohibit prescribing controlled or non-controlled medications based solely on the telehealth modality. Oral estradiol is not a controlled substance, so no additional regulatory hurdle applies beyond the standard prescriber-patient relationship requirements.

A Delaware patient seeking oral estradiol through a telehealth platform typically goes through the following steps:

1. Completes an intake questionnaire covering symptom history, contraindication screening (active or history of estrogen-dependent cancer, undiagnosed vaginal bleeding, active DVT or PE, and liver disease are the primary contraindications per the FDA label), and current medications.
2. Has a synchronous video or asynchronous (store-and-forward) consultation with a licensed Delaware prescriber or an out-of-state prescriber with a Delaware telehealth registration.
3. Receives an electronic prescription sent directly to a Delaware pharmacy of their choice, or to a mail-order pharmacy licensed in Delaware.

Most telehealth HRT platforms charge a consultation fee of $25 to $99 for the initial visit, with follow-up visits ranging from $0 to $49. The prescription itself is then filled at standard cash-pay or insurance rates described above. HealthRX offers telehealth HRT consultations with licensed providers and can send prescriptions to any Delaware pharmacy.

The Cheapest Realistic Pathway for a Delaware Patient in 2026

For a Delaware patient without insurance or with insurance that places estradiol at an expensive tier, the cheapest realistic pathway to oral estradiol in 2026 follows this sequence:

Check whether Medicaid eligibility applies first. DMAP income eligibility for adults in Delaware in 2026 covers individuals up to 138% of the federal poverty level (FPL). A single adult earning up to approximately $20,783 per year qualifies. Medicaid-approved estradiol costs $0 to $3 per fill after PA approval.

For patients above that income threshold, a GoodRx or similar discount card applied at a high-volume pharmacy (Costco, Walmart, or Kroger pharmacies in the Wilmington area) brings generic estradiol 1 mg to as low as $9 per 30-day supply. That is the cash-pay floor for most Delaware ZIP codes as of early 2026.

The Delaware Prescription Assistance Program (DPAP), administered through the Delaware Department of Health and Social Services, provides additional drug assistance for adults who do not qualify for Medicaid but have low-to-moderate income. DPAP can reduce or eliminate copays for covered medications including hormone therapies.

Generic manufacturer patient assistance programs (PAPs) are less relevant for estradiol specifically because the medication is already so inexpensive at retail, but they exist for patients who cannot afford even the discounted cash price.

What a Delaware Prescriber Reviews Before Writing the Prescription

Any clinician, whether seen in person at a Wilmington gynecology practice or via telehealth, will screen for contraindications before prescribing oral estradiol. The FDA-approved label lists absolute contraindications including: undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent neoplasia, active DVT or pulmonary embolism, active arterial thromboembolic disease, known anaphylactic reaction or angioedema to estradiol, known liver impairment or disease, and known or suspected pregnancy.

Beyond contraindications, the prescriber will typically discuss the timing hypothesis. Evidence from the WHI and its subsequent reanalyses suggests women who begin hormone therapy within 10 years of menopause onset or before age 60 have a more favorable cardiovascular risk profile than those who begin therapy later. A 2017 analysis published in the Journal of Clinical Endocrinology and Metabolism (N=9,489) found that initiating estrogen therapy within five years of menopause was associated with a 32% lower risk of coronary heart disease events compared with initiating more than 10 years after menopause onset. That reanalysis and related data are available through the NIH National Library of Medicine.

The prescriber will also assess whether a progestogen needs to be co-prescribed. Women with an intact uterus require concurrent progestogen (most commonly micronized progesterone 100 mg or 200 mg at bedtime, or medroxyprogesterone acetate 2.5 mg daily) to protect the endometrium from unopposed estrogen stimulation. Women who have had a hysterectomy may take estradiol alone.

Dose Forms and Titration Schedule in Delaware Clinical Practice

Oral estradiol tablets are available in 0.5 mg, 1 mg, and 2 mg strengths. Most Delaware clinicians initiate therapy at 1 mg once daily for moderate-to-severe vasomotor symptoms and reassess at 8 to 12 weeks. Patients whose symptoms remain poorly controlled may titrate to 2 mg daily; those experiencing side effects (breast tenderness, bloating, headache) may step down to 0.5 mg.

Tablets should be swallowed whole and can be taken with or without food. Unlike sublingual or buccal estradiol (which are not FDA-approved formulations), standard oral tablets undergo first-pass hepatic metabolism, resulting in higher circulating estrone relative to estradiol. This metabolic characteristic is one reason some clinicians prefer transdermal patches or gels for patients with a personal or family history of venous thromboembolism, as the transdermal route bypasses first-pass metabolism and produces less hepatic stimulation of clotting factors.

That clinical nuance does not change the cost picture, but it does mean a prescriber may switch a Delaware patient from oral to transdermal estradiol based on individual risk factors, and the cost calculation changes accordingly.

Monitoring After Starting Oral Estradiol

Standard practice includes a follow-up visit at 8 to 12 weeks after initiation to assess symptom control, side effects, and blood pressure (estrogen can modestly raise blood pressure in susceptible individuals). No routine serum estradiol level monitoring is required by clinical guidelines for symptomatic management, though some clinicians check levels at 6 to 8 weeks to confirm absorption, particularly if a patient reports no symptom improvement.

Annual follow-up should include a review of ongoing indication, a breast exam, and, per the U.S. Preventive Services Task Force (USPSTF), mammography screening consistent with the patient's age-appropriate schedule. The USPSTF recommends biennial mammography for average-risk women aged 40 to 74. That recommendation is available at the USPSTF website.

Bone density (DEXA scan) is not required before starting estradiol for vasomotor symptoms, but estradiol does preserve bone mineral density. Women at elevated fracture risk may receive dual benefit from hormone therapy, a consideration relevant for Delaware's aging population where osteoporosis affects an estimated 10.2% of women over 50 per CDC surveillance data.